ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0579

Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Abstract Number: 0580

Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting
Abstract Number: 0581

A Proposed Economic Framework to Model the Consequences of Psoriatic Arthritis Disease Domains
Abstract Number: 0582

Mortality and Cost of Hospitalization: Do Hospitals Caring for More SLE Patients Perform Better?
Abstract Number: 0583

Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 0584

Total Cost of Care for Patients with Rheumatoid Arthritis
Abstract Number: 0585

Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis
Abstract Number: 0586

Performance Characteristics of ANA by Elisa and Immunofluorescence
Abstract Number: 0587

Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Abstract Number: 0588

Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices
Abstract Number: 0589

The Ideal Mhealth Application for Rheumatoid Arthritis: Qualitative Findings from Stakeholder Focus Groups
Abstract Number: 0590

A Web-Based Data Capture System Can Successfully Collect Detailed and Quantifiable Physical Therapy Intervention Data Post Total Knee Replacement
Abstract Number: 0591

Intervention to Improve SLE Medication Adherence Using Surescripts Pharmacy Refill Data
Abstract Number: 0592

A Rheumatology-Driven Protocol and Treatment Algorithm of SARS-CoV-2 Cytokine Release Syndrome and Its Associated Outcomes
Abstract Number: 0593

Patient Characteristics and Factors Affecting Decision-Making Regarding Total Knee Replacement by Different Types of Physicians Treating Patients with Knee OA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].